89bio reports second quarter 2023 financial results and provides corporate update

– published data from enliven phase 2b trial of pegozafermin in nash in the new england journal of medicine; presented the data in a late-breaker session at the easl international liver congress –
ETNB Ratings Summary
ETNB Quant Ranking